Cargando…

Corneal Opacity Induced by Antiglaucoma Agents Other Than Brimonidine Tartrate

The aim of this study is to report a patient with corneal opacity that developed after the use of topical antiglaucoma medications other than brimonidine tartrate (BT). An 85-year-old woman presented with corneal opacity and neovascularization in both eyes. A diagnosis of glaucoma was made 20 years...

Descripción completa

Detalles Bibliográficos
Autores principales: Kasuya, Yuka, Sano, Ichiya, Makino, Shinji, Kawashima, Hidetoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7273428/
https://www.ncbi.nlm.nih.gov/pubmed/32547800
http://dx.doi.org/10.1155/2020/4803651
_version_ 1783542402467758080
author Kasuya, Yuka
Sano, Ichiya
Makino, Shinji
Kawashima, Hidetoshi
author_facet Kasuya, Yuka
Sano, Ichiya
Makino, Shinji
Kawashima, Hidetoshi
author_sort Kasuya, Yuka
collection PubMed
description The aim of this study is to report a patient with corneal opacity that developed after the use of topical antiglaucoma medications other than brimonidine tartrate (BT). An 85-year-old woman presented with corneal opacity and neovascularization in both eyes. A diagnosis of glaucoma was made 20 years previously, and antiglaucoma agents were prescribed (latanoprost, tafluprost, timolol maleate, travoprost, bimatoprost, ripasudil hydrochloride hydrate, and brinzolamide/timolol maleate) for both eyes. Ocular examination revealed semicircular fan-shaped corneal sterile infiltration with neovascularization. Anterior-segment optical coherence tomography (OCT) showed marked corneal opacity and thickened corneal stroma. The topical drugs were discontinued and replaced with 0.1% betamethasone eye drops. Two weeks after topical drugs were discontinued and replaced with betamethasone, the corneal sterile infiltration markedly improved, although the corneal opacity remained across the stromal layer. In addition, corneal opacity, intermixed with separate transparent sections, was observed as a striped shape. OCT showed an improvement of the thickened corneal stroma. Six weeks after the initial visit, the remaining corneal opacity could be seen as a mixture of opaque and nonopaque areas in stripes. The corneal stromal thickness decreased almost back to the normal range, while the area of the corneal opacity remained unchanged. In vivo laser confocal microscopy showed hyperreflective materials with needle-like structures in the corneal stroma. The corneal opacity showed several similarities to the previous reports of the cases treated with BT. Therefore, clinicians should be mindful of a possible development of corneal opacity in patients treated with antiglaucoma medications other than BT.
format Online
Article
Text
id pubmed-7273428
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-72734282020-06-15 Corneal Opacity Induced by Antiglaucoma Agents Other Than Brimonidine Tartrate Kasuya, Yuka Sano, Ichiya Makino, Shinji Kawashima, Hidetoshi Case Rep Ophthalmol Med Case Report The aim of this study is to report a patient with corneal opacity that developed after the use of topical antiglaucoma medications other than brimonidine tartrate (BT). An 85-year-old woman presented with corneal opacity and neovascularization in both eyes. A diagnosis of glaucoma was made 20 years previously, and antiglaucoma agents were prescribed (latanoprost, tafluprost, timolol maleate, travoprost, bimatoprost, ripasudil hydrochloride hydrate, and brinzolamide/timolol maleate) for both eyes. Ocular examination revealed semicircular fan-shaped corneal sterile infiltration with neovascularization. Anterior-segment optical coherence tomography (OCT) showed marked corneal opacity and thickened corneal stroma. The topical drugs were discontinued and replaced with 0.1% betamethasone eye drops. Two weeks after topical drugs were discontinued and replaced with betamethasone, the corneal sterile infiltration markedly improved, although the corneal opacity remained across the stromal layer. In addition, corneal opacity, intermixed with separate transparent sections, was observed as a striped shape. OCT showed an improvement of the thickened corneal stroma. Six weeks after the initial visit, the remaining corneal opacity could be seen as a mixture of opaque and nonopaque areas in stripes. The corneal stromal thickness decreased almost back to the normal range, while the area of the corneal opacity remained unchanged. In vivo laser confocal microscopy showed hyperreflective materials with needle-like structures in the corneal stroma. The corneal opacity showed several similarities to the previous reports of the cases treated with BT. Therefore, clinicians should be mindful of a possible development of corneal opacity in patients treated with antiglaucoma medications other than BT. Hindawi 2020-05-26 /pmc/articles/PMC7273428/ /pubmed/32547800 http://dx.doi.org/10.1155/2020/4803651 Text en Copyright © 2020 Yuka Kasuya et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Kasuya, Yuka
Sano, Ichiya
Makino, Shinji
Kawashima, Hidetoshi
Corneal Opacity Induced by Antiglaucoma Agents Other Than Brimonidine Tartrate
title Corneal Opacity Induced by Antiglaucoma Agents Other Than Brimonidine Tartrate
title_full Corneal Opacity Induced by Antiglaucoma Agents Other Than Brimonidine Tartrate
title_fullStr Corneal Opacity Induced by Antiglaucoma Agents Other Than Brimonidine Tartrate
title_full_unstemmed Corneal Opacity Induced by Antiglaucoma Agents Other Than Brimonidine Tartrate
title_short Corneal Opacity Induced by Antiglaucoma Agents Other Than Brimonidine Tartrate
title_sort corneal opacity induced by antiglaucoma agents other than brimonidine tartrate
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7273428/
https://www.ncbi.nlm.nih.gov/pubmed/32547800
http://dx.doi.org/10.1155/2020/4803651
work_keys_str_mv AT kasuyayuka cornealopacityinducedbyantiglaucomaagentsotherthanbrimonidinetartrate
AT sanoichiya cornealopacityinducedbyantiglaucomaagentsotherthanbrimonidinetartrate
AT makinoshinji cornealopacityinducedbyantiglaucomaagentsotherthanbrimonidinetartrate
AT kawashimahidetoshi cornealopacityinducedbyantiglaucomaagentsotherthanbrimonidinetartrate